Premium
Erythropoietin for neonatal brain injury: opportunity and challenge
Author(s) -
Xiong Tao,
Qu Yi,
Mu Dezhi,
Ferriero Donna
Publication year - 2011
Publication title -
international journal of developmental neuroscience
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.761
H-Index - 88
eISSN - 1873-474X
pISSN - 0736-5748
DOI - 10.1016/j.ijdevneu.2010.12.007
Subject(s) - erythropoietin , neuroprotection , medicine , encephalopathy , hypothermia , dosing , neonatal encephalopathy , hypoxic ischemic encephalopathy , hypoxia (environmental) , ischemia , brain damage , clinical trial , intensive care medicine , bioinformatics , pharmacology , anesthesia , biology , chemistry , organic chemistry , oxygen
Neonatal brain injury, caused by perinatal hypoxia‐ischemia and extreme prematurity, remains a great challenge for prevention and treatment. There is no effective treatment for term hypoxic‐ischemic encephalopathy (HIE) except hypothermia which by itself does not afford complete neuroprotection. Erythropoietin (EPO), a pleiotropic cytokine, has neuroprotective effects in a series of neonatal experimental models and recent clinical trials of HIE. However, the mechanisms, dosing, and the toxicity of EPO in these settings are inconsistently reported. This review will focus on the possible mechanisms, recent clinical advances and potential complications of EPO used in research and the clinic. In addition, optimal dose and administrative routes of EPO, and novel EPO mimetics will be discussed.